和铂医药-B(02142)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02142 和铂医药-B

交易中 08-20 14:33:59

16.410

+1.920

+13.25%

最高16.620	最低14.970	成交量1,588万
今开15.150	昨收14.490	日振幅11.39%
总市值142.60亿	流通市值142.60亿	总股本8.69亿
成交额2.56亿	换手率1.83%	流通股本8.69亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02142","market":"HK","secType":"STK","nameCN":"和铂医药-B","latestPrice":16.41,"timestamp":1787207625853,"preClose":14.49,"halted":0,"volume":15879000,"delay":0,"changeRate":0.13250517598343683,"floatShares":869000000,"shares":869000000,"eps":0.8626503756450272,"marketStatus":"交易中","change":1.92,"latestTime":"08-20 14:33:59","open":15.15,"high":16.62,"low":14.97,"amount":256312233,"amplitude":0.113872,"askPrice":16.41,"askSize":5000,"bidPrice":16.39,"bidSize":16000,"shortable":3,"etf":0,"ttmEps":0.862642533368885,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1787213400000},"marketStatusCode":2,"adr":0,"listingDate":1607529600000,"exchange":"SEHK","adjPreClose":14.49,"openAndCloseTimeList":[[1787189400000,1787198400000],[1787202000000,1787212800000]],"volumeRatio":4.703,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02142","defaultTab":"news","newsList":[{"id":"1143839405","title":"和铂医药-B（02142）B7H4×CD3双抗HBM7004获国家药监局临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1143839405","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1143839405?lang=zh_cn&edition=full","pubTime":"2026-08-18 17:06","pubTimestamp":1787043995,"startTime":"0","endTime":"0","summary":"2026年8月18日，和铂医药控股有限公司发布自愿公告称，其新型B7H4×CD3双特异性抗体HBM7004治疗晚期实体瘤的新药临床试验申请已获中国国家药品监督管理局批准。此次获批系继2026年5月8日美国食品药品监督管理局批准HBM7004在美开展首次人体I期临床试验后，项目迎来的又一里程碑。公司在公告中重申，目前无法保证HBM7004能最终成功开发或上市，提醒股东及潜在投资者买卖公司股份时保持审慎。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660463474","title":"和铂医药-B(02142)：HBM7004用于治疗晚期实体瘤的新药临床试验申请获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2660463474","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660463474?lang=zh_cn&edition=full","pubTime":"2026-08-18 17:03","pubTimestamp":1787043804,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和铂医药-B 公布，HBM7004的新药临床试验申请已获中国国家药品监督管理局批准。据悉，HBM7004是一款新型B7H4xCD3双特异性抗体，开发自集团专有的HBICE平台，从疗效和安全性两个维度为癌症免疫治疗提供差异化解决方案。HBM7004的开发进一步彰显了HBICE平台的灵活适用性和即插即用优势。在临床前研究中，HBM7004呈现出肿瘤内B7H4依赖性T细胞激活机制。在多种动物模型实验中，HBM7004表现出强劲的抗肿瘤效果、出色的体内稳定性以及较低的全身毒性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1481365.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["MDTX","IBBJ","PSYK","BK1161","BMED","BK1574","IBBQ","BK1583","02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155766563","title":"和铂医药-B（02142）拟于8月27日召开董事会审议2026年中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1155766563","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1155766563?lang=zh_cn&edition=full","pubTime":"2026-08-17 16:41","pubTimestamp":1786956094,"startTime":"0","endTime":"0","summary":"和铂医药-B（02142）8月17日发布公告称，公司董事会将于2026年8月27日（星期四）召开会议，主要议程包括审议并批准本集团截至2026年6月30日止六个月的中期业绩，以及处理其他相关事项。\n公告显示，董事会现由两名执行董事王劲松博士、戎一平博士，以及四名独立非执行董事Robert Irwin Kamen博士、叶小平博士、Albert R. Collinson博士和陈维维女士组成。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657698217","title":"港股异动 | 和铂医药-B(02142)早盘涨超7% 上半年收入增长并盈利 近期与国药集团达成战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2657698217","media":"智通财经","labels":["corporation","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657698217?lang=zh_cn&edition=full","pubTime":"2026-08-07 10:49","pubTimestamp":1786070969,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，和铂医药-B(02142)早盘涨超7%，截至发稿，涨7.23%，报13.65港元，成交额3403.36万港元。消息面上，和铂医药近日发布盈喜，预计2026上半年实现营业收入1.2-1.25亿美元；期内净利0.62-0.67亿美元。主要源于与全球跨国药企达成的持续战略合作；创新产品对外授权及合作确认收入款项；诺纳生物抗体相关业务实现强劲增长。值得注意的是，7月公司与国药集团签署战略合作，以建立国药集团-和铂医药创新联合体，并就创新型生物药的研发领域开展合作，战略重点覆盖肿瘤及免疫炎症等疾病领域。根据协议双方将共同承担研发成本、共同享有产品权益。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477154.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02142","BK1583","BK1574","VXUS","BK1161","BK4588","KCAI","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132810179","title":"和铂医药-B更新2026年7月股份变动月报表，股本规模小幅上升","url":"https://stock-news.laohu8.com/highlight/detail?id=1132810179","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132810179?lang=zh_cn&edition=full","pubTime":"2026-08-06 22:40","pubTimestamp":1786027240,"startTime":"0","endTime":"0","summary":"和铂医药控股有限公司于2026年8月6日发布截至2026年7月31日的月度证券变动报告。公告显示，公司本月维持20,000,000,000股法定/注册股本不变，股本面值每股0.000025美元，总面值仍为500,000美元。公告显示，和铂医药-B确认在本月末继续满足联交所关于最低公众持股量的相关规定。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144732116","title":"和铂医药-B任命张博博士为代谢疾病事业部总裁，加速全球创新疗法研发","url":"https://stock-news.laohu8.com/highlight/detail?id=1144732116","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144732116?lang=zh_cn&edition=full","pubTime":"2026-08-06 16:12","pubTimestamp":1786003936,"startTime":"0","endTime":"0","summary":"和铂医药-B（HBM HOLDINGS-B）宣布了一项重要人事任命：张博博士正式出任公司代谢疾病事业部总裁。这一举措旨在推动其创新疗法在全球范围内的开发进程，进一步巩固公司在代谢疾病领域的战略布局。张博博士将全面负责该事业部的全球战略规划、研发管线拓展以及商业化运营，为和铂医药在代谢疾病领域的创新疗法注入强劲动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","02142","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655832649","title":"【券商聚焦】国泰海通证券：全球多肽CDMO进入产能扩张周期","url":"https://stock-news.laohu8.com/highlight/detail?id=2655832649","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655832649?lang=zh_cn&edition=full","pubTime":"2026-07-29 09:21","pubTimestamp":1785288070,"startTime":"0","endTime":"0","summary":"国内外的多肽CDMO公司均加大对于产能的投资建设，尤其注重从临床前到商业化生产的一站式服务能力建设。2026年4月，凯莱英医药与天津经开区管委会签署合作备忘录，在天津经开区持续扩建化学大分子创新药CDMO研发生产基地，预计投资规模达20亿元人民币。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/MWIyNWQwZjQ4NTQyNjI4OTI5NDE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWIyNWQwZjQ4NTQyNjI4OTI5NDE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986985","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02611","06185","LU1328277881.USD","LU0307460666.USD","BK1147","IE00B543WZ88.USD","LU0979878070.USD","BK1574","09926","LU2476274308.USD","161027","01801","BK1610","IE00B5MMRT66.SGD","KURE","CDMO","LU0067412154.USD","SG9999002463.SGD","LU0051755006.USD","LU0634319403.HKD","06160","LU0359202008.SGD","LU0588546209.SGD","02142","LU2242644610.SGD","KCE","BK1588","BK1564","LU0348784397.USD","LU0561508036.HKD","02616","BK1583","601211","LU0181495838.USD","LU0417516738.SGD","LU1719994722.HKD","HK0000165453.HKD","09995","01177","09688","02269","01093","LU1251922891.USD","LU1720050803.USD","LU0052750758.USD","LU1008478684.HKD","BK1141","01877","IE00B0JY6N72.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654016344","title":"和铂医药与国药集团战略合作 拓创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2654016344","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654016344?lang=zh_cn&edition=full","pubTime":"2026-07-27 17:39","pubTimestamp":1785145184,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1583","06978","BK1161","02142","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185769222","title":"和铂医药-B（02142）携手国药集团组建创新联合体　共推肿瘤及免疫炎症生物药研发","url":"https://stock-news.laohu8.com/highlight/detail?id=1185769222","media":"公告速递","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1185769222?lang=zh_cn&edition=full","pubTime":"2026-07-27 17:05","pubTimestamp":1785143146,"startTime":"0","endTime":"0","summary":"和铂医药-B7月27日发布自愿公告称，公司已与中国医药集团有限公司签署战略合作协议，双方将成立“国药集团—和铂医药创新联合体”，围绕创新型生物药全生命周期开展合作，重点聚焦肿瘤及免疫炎症等疾病领域。根据协议，和铂医药-B将依托其全人源抗体技术平台Harbour Mice及人工智能赋能的药物研发能力，与国药集团共同进行候选抗体分子的发现与优化，涵盖靶点确认、先导抗体发现及优化、抗体构型设计和抗体工程等环节。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654015307","title":"和铂医药-B(02142)与国药集团签署战略合作协议 以建立国药集团-和铂医药创新联合体","url":"https://stock-news.laohu8.com/highlight/detail?id=2654015307","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654015307?lang=zh_cn&edition=full","pubTime":"2026-07-27 17:02","pubTimestamp":1785142967,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和铂医药-B 发布公告，本公司已与中国医药集团有限公司签署战略合作协议，以建立国药集团-和铂医药创新联合体，并就创新型生物药的研发领域开展合作，战略重点覆盖肿瘤及免疫炎症等疾病领域。根据战略合作，本集团与国药集团将围绕创新型生物药的全生命周期开展研发合作，战略重点覆盖肿瘤及免疫炎症等疾病领域。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1472594.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1161","BK1574","02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198876424","title":"和铂医药-B与中国医药集团达成生物药研发战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1198876424","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198876424?lang=zh_cn&edition=full","pubTime":"2026-07-27 17:02","pubTimestamp":1785142960,"startTime":"0","endTime":"0","summary":"和铂医药-B（HBM Holdings-B）正式宣布，已与中国医药集团有限公司（国药集团）签署战略合作协议，双方将聚焦生物药研发领域展开深度协作。此次合作标志着这家专注于创新疗法的生物技术公司，在拓展国内战略伙伴关系方面迈出了关键一步。根据协议，双方将整合各自在生物药研发、技术平台及产业化资源上的优势，共同推进包括新型抗体药物在内的前沿项目。这一合作不仅有望加速候选药物的临床转化进程，也为和铂医药在生物药领域的长远布局注入了新的动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","02142","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653705587","title":"港股异动 | 和铂医药-B(02142.HK)盈喜后涨超4% 预计中期溢利约6200万美元至约6700万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2653705587","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653705587?lang=zh_cn&edition=full","pubTime":"2026-07-24 09:33","pubTimestamp":1784856788,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","02142","BK1161","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112421585","title":"和铂医药-B披露正面盈利预告：上半年收入最高1.25亿美元，预计实现盈利","url":"https://stock-news.laohu8.com/highlight/detail?id=1112421585","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1112421585?lang=zh_cn&edition=full","pubTime":"2026-07-24 08:06","pubTimestamp":1784851570,"startTime":"0","endTime":"0","summary":"2026年7月24日，和铂医药-B发布正面盈利预告称，根据截至2026年6月30日止六个月的初步未审计管理账目，预计期内收入介乎约1.2亿美元至1.25亿美元，较2025年同期1.01亿美元显著增长。公司同时预期，上半年溢利将在约62百万美元至67百万美元之间；经调整溢利总额预计为70百万美元至75百万美元。和铂医药-B表示，以上财务数据尚未经过董事会旗下审核委员会或公司核数师的审阅，最终业绩将于2026年8月底发布的中期业绩公告中披露。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653772889","title":"和铂医药-B(02142)发盈喜 预计中期溢利约6200万美元至约6700万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2653772889","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653772889?lang=zh_cn&edition=full","pubTime":"2026-07-24 08:05","pubTimestamp":1784851541,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和铂医药-B 发布公告，预期截至2026年6月30日止六个月的收入介乎约1.2亿美元至约1.25亿美元，而截至2025年6月30日止六个月的收入则为约1.01亿美元。预期截至2026年6月30日止六个月的溢利介乎约6200万美元至约6700万美元。预期经调整溢利总额介乎7000万美元至7500万美元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1471717.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1161","02142","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653772662","title":"和铂医药发布2026年中期盈利预喜：实现连续七个半年度盈利，平台型药企优势助力业绩可持续增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2653772662","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653772662?lang=zh_cn&edition=full","pubTime":"2026-07-24 08:02","pubTimestamp":1784851320,"startTime":"0","endTime":"0","summary":"中国上海，美国马萨诸塞州剑桥和荷兰鹿特丹2026年7月24日 /美通社/ -- 和铂医药，一家专注于免疫性疾病、肿瘤及其他领域创新抗体疗法发现及开发的全球生物医药公司，今日发布截至2026年6月30日的中期业绩盈利预喜。和铂医药实现连续七个半年度盈利，标志着公司正式跨入\"常态化盈利\"阶段，进一步验证了平台型制药集团商业模式的可持续性和可复制性。报告期内，公司多项重磅合作贡献显著收入。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5010897_ZH10897_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5010897_ZH10897_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1583","BK1161","BK1574","02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130107379","title":"和铂医药与维也纳医科大学达成研究合作，共同推进感染性疾病全人源抗体开发","url":"https://stock-news.laohu8.com/highlight/detail?id=1130107379","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1130107379?lang=zh_cn&edition=full","pubTime":"2026-07-23 08:56","pubTimestamp":1784768173,"startTime":"0","endTime":"0","summary":"和铂医药宣布，已与维也纳医科大学建立研究合作关系，双方将携手推进针对感染性疾病的全人源抗体开发项目。此项合作旨在利用和铂医药的专有技术平台与维也纳医科大学的学术研究专长，加速创新疗法的发现与转化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142","BK1161","BK1583","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652036024","title":"港股异动 | 和铂医药-B(02142.HK)盘中跌超10% 辉瑞宣布终止和铂ADC药物SGN-MesoC2全部研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2652036024","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652036024?lang=zh_cn&edition=full","pubTime":"2026-07-17 15:53","pubTimestamp":1784274820,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","BK1574","BK1583","02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651145145","title":"和铂医药-B(02142)：HBM7575用于治疗哮喘的新药临床试验申请获NMPA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2651145145","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651145145?lang=zh_cn&edition=full","pubTime":"2026-07-15 18:02","pubTimestamp":1784109738,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和铂医药-B(02142)公布，靶向胸腺基质淋巴细胞生成素(TSLP)及一个未公开靶点的长效双特异性抗体HBM7575(亦称SKB575)的新药临床试验(IND)申请已获中国国家药品监督管理局(NMPA)批准，用于治疗哮喘。该款双特异性抗体由公司与四川科伦博泰生物医药股份有限公司(科伦博泰) (06990)合作研发。此前，HBM7575/SKB575用于治疗特应性皮炎的I期临床研究已顺利完成首例受试者给药。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1467931.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","IBBQ","02142","BK1583","BMED","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651991128","title":"【券商聚焦】中信证券：新基药目录有望加速创新药基层落地","url":"https://stock-news.laohu8.com/highlight/detail?id=2651991128","media":"金吾财讯","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651991128?lang=zh_cn&edition=full","pubTime":"2026-07-14 08:57","pubTimestamp":1783990650,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信证券研究指，《2026年版国家基本药物目录》于7月9日正式发布，将于9月1日起实施。该机构认为，本次新版基药目录新增药物均已属于医保药品，随着基药与医保的深度协同联动，有望极大加速创新药的基层落地，医保控费与创新回报形成良性循环。","market":"us","thumbnail":"https://static.szfiu.com/news/20250106/ZGNkM2E3NDVjMTk0N2Q5ZDk4NjYxNjc1YjA4NjMzOTA5MjkwMDE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZGNkM2E3NDVjMTk0N2Q5ZDk4NjYxNjc1YjA4NjMzOTA5MjkwMDE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985769","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995","IE00BPRC5H50.USD","LU0359201612.USD","LU0327786744.USD","SG9999002463.SGD","LU1226288253.USD","09926","LU0051755006.USD","600030","01801","LU0043850808.USD","LU2476274720.SGD","LU0823426480.USD","LU1961090484.USD","LU0572944931.SGD","HK0000165453.HKD","LU2039709279.SGD","LU1997244956.HKD","MEDX","LU0417516902.SGD","IBBQ","IE0008368742.USD","LU1226287792.SGD","LU2488822045.USD","01177","LU0588546209.SGD","02142","01877","06185","01093","LU0314109678.HKD","LU0979878070.USD","BK1161","BK1610","LU2328871848.SGD","09688","06978","KCE","06030","LU0405327494.USD","02269","06160","KURE","LU1152091168.USD","BK1500","LU1242518931.SGD","LU1960683339.HKD","02616","159992","LU1328277881.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651568164","title":"【券商聚焦】中信建投：创新药企仍是高增长主线、BD交易持续催化业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2651568164","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651568164?lang=zh_cn&edition=full","pubTime":"2026-07-13 08:53","pubTimestamp":1783903985,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指出，1）制药产业链：创新药企仍是高增长主线，BD交易持续催化业绩。BD授权收入成为多家公司中期业绩关键变量。上游供应链受益于国产替代及下游需求恢复，Q2增速普遍提升，利润端弹性显著。建议关注Q2高增长公司的配置机会。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/NWI3NDNkNGUxZmM1MTMzOTE0MzEwMTk=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NWI3NDNkNGUxZmM1MTMzOTE0MzEwMTk=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985645","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0359202008.SGD","IBBQ","09688","02616","LU1993786604.SGD","01093","LU0456846285.SGD","LU0348825331.USD","LU0516422366.SGD","LU2097828474.EUR","159992","LU0501845795.SGD","LU1969619763.USD","LU1688375341.USD","IE0008369823.USD","09926","IE00B0JY6N72.USD","01177","BK1588","01801","06978","BK1161","IE0008368742.USD","LU0455707207.USD","KURE","601066","LU1960683339.HKD","LU2488822045.USD","LU0359201612.USD","LU0348784397.USD","LU0067412154.USD","IE00B5MMRT66.SGD","LU0348735423.USD","LU1961090484.USD","06160","06185","BK1515","LU1226288170.HKD","LU0051755006.USD","LU1813983027.USD","09995","LU1807302812.USD","02269","LU2097828631.EUR","KCE","02142","MEDX","LU2242644610.SGD","01877","BD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0359},{"period":"1month","weight":0.2332},{"period":"3month","weight":0.2187},{"period":"6month","weight":0.1838},{"period":"1year","weight":0.1848},{"period":"ytd","weight":0.1916}],"compareEarnings":[{"period":"1week","weight":0.0022},{"period":"1month","weight":0.014},{"period":"3month","weight":0.0043},{"period":"6month","weight":-0.0348},{"period":"1year","weight":0.0148},{"period":"ytd","weight":-0.0053}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"和铂医药控股有限公司是一家主要从事肿瘤免疫学及免疫性疾病领域的创新疗法开发业务的投资控股公司。该公司的产品主要包括巴托利单抗（HBM9161）、HBM9378、HBM7020、TCE Program、普鲁苏拜单抗（HBM4003）以及HBM7022等。该公司产品主要用于治疗全身型重症肌无力（gMG）、慢性阻塞性肺病（COPD）、哮喘、自身免疫疾病、黑色素瘤、结直肠癌以及实体瘤等。该公司通过专有抗体技术平台“Harbour Mice”、“HBICE”、“HBICA”及单克隆B细胞筛选平台提供下一代抗体以及生物解决方案。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.083377},{"month":2,"riseRate":0.333333,"avgChangeRate":0.000026},{"month":3,"riseRate":0.5,"avgChangeRate":0.051559},{"month":4,"riseRate":0.333333,"avgChangeRate":0.009952},{"month":5,"riseRate":0.5,"avgChangeRate":0.016802},{"month":6,"riseRate":0.166667,"avgChangeRate":-0.072876},{"month":7,"riseRate":0.5,"avgChangeRate":0.053076},{"month":8,"riseRate":0.333333,"avgChangeRate":0.036296},{"month":9,"riseRate":0.4,"avgChangeRate":-0.065735},{"month":10,"riseRate":0,"avgChangeRate":-0.180686},{"month":11,"riseRate":0.8,"avgChangeRate":0.25789},{"month":12,"riseRate":0.6,"avgChangeRate":0.266929}],"exchange":"SEHK","name":"和铂医药-B","nameEN":"HBM HOLDINGS-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"和铂医药-B(02142)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供和铂医药-B(02142)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"和铂医药-B,02142,和铂医药-B股票,和铂医药-B股票老虎,和铂医药-B股票老虎国际,和铂医药-B行情,和铂医药-B股票行情,和铂医药-B股价,和铂医药-B股市,和铂医药-B股票价格,和铂医药-B股票交易,和铂医药-B股票购买,和铂医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"和铂医药-B(02142)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供和铂医药-B(02142)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}